3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Breast
1
Conditions
Pancreatic Neoplasms
3
Inflammation
2
Glioblastoma
2
Frailty
2
Recurrence
1
Polycystic Ovary Syndrome
1
Obesity
1
Neoplasms
1
Neoplasm Metastasis
1
Myofibroma
1
Multiple Myeloma
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Lung Neoplasms
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Acute
1
Hodgkin Disease
1
Hemorrhage
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Anemia
1
Adenomyosis
1
Adenocarcinoma
1
Interventions
Cyclophosphamide
51
fludarabine
37
Dexamethasone
35
venetoclax
30
pembrolizumab
25
Rituximab
20
pomalidomide
18
Lenalidomide
17
Gemcitabine
17
fludarabine phosphate
15
Etoposide
14
Cytarabine
13
daratumumab
12
carfilzomib
11
Temozolomide
11
Injections
10
Calcium Dobesilate
10
glofitamab
9
Nivolumab
9
Cisplatin
9
Bortezomib
9
Azacitidine
9
selinexor
8
Vincristine
8
Immunotherapy, Adoptive
8
obinutuzumab
7
cemiplimab
7
Drug Therapy
7
Carboplatin
7
zanubrutinib
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrence
×
Ascorbic Acid
×
1 year
×
Clear all
NCT04150042
2026-01-29
SHARON
General Oncology, Inc.
Phase 1
Recruiting
24 enrolled